Literature DB >> 23017997

DNA damage: placing BRCA1 in the proper context.

Bernadette Aressy1, Roger A Greenberg.   

Abstract

How does BRCA1's evolutionarily conserved E3 ligase activity contribute to DNA damage responses? Genetically engineered cells containing a BRCA1 RING domain mutation have been used to identify Claspin as a new target of BRCA1 E3 ligase activity in response to specific forms of DNA damage.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23017997      PMCID： PMC3827951          DOI： 10.1016/j.cub.2012.07.046

Source DB:  PubMed          Journal:  Curr Biol        ISSN： 0960-9822            Impact factor:   10.834


  17 in total

1.  BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity.

Authors:  Reena Shakya; Latarsha J Reid; Colleen R Reczek; Francesca Cole; Dieter Egli; Chyuan-Sheng Lin; Dirk G deRooij; Steffen Hirsch; Kandasamy Ravi; James B Hicks; Matthias Szabolcs; Maria Jasin; Richard Baer; Thomas Ludwig
Journal:  Science       Date:  2011-10-28       Impact factor: 47.728

2.  Loss of CHK1 function impedes DNA damage-induced FANCD2 monoubiquitination but normalizes the abnormal G2 arrest in Fanconi anemia.

Authors:  Jean-Hugues Guervilly; Gaëtane Macé-Aimé; Filippo Rosselli
Journal:  Hum Mol Genet       Date:  2007-11-20       Impact factor: 6.150

3.  BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair.

Authors:  Samuel F Bunting; Elsa Callén; Marina L Kozak; Jung Min Kim; Nancy Wong; Andrés J López-Contreras; Thomas Ludwig; Richard Baer; Robert B Faryabi; Amy Malhowski; Hua-Tang Chen; Oscar Fernandez-Capetillo; Alan D'Andrea; André Nussenzweig
Journal:  Mol Cell       Date:  2012-03-22       Impact factor: 17.970

4.  Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway.

Authors:  I Garcia-Higuera; T Taniguchi; S Ganesan; M S Meyn; C Timmers; J Hejna; M Grompe; A D D'Andrea
Journal:  Mol Cell       Date:  2001-02       Impact factor: 17.970

Review 5.  Topoisomerase I inhibitors: camptothecins and beyond.

Authors:  Yves Pommier
Journal:  Nat Rev Cancer       Date:  2006-10       Impact factor: 60.716

6.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.

Authors:  Andrew Tutt; Mark Robson; Judy E Garber; Susan M Domchek; M William Audeh; Jeffrey N Weitzel; Michael Friedlander; Banu Arun; Niklas Loman; Rita K Schmutzler; Andrew Wardley; Gillian Mitchell; Helena Earl; Mark Wickens; James Carmichael
Journal:  Lancet       Date:  2010-07-06       Impact factor: 79.321

7.  E3 ligase activity of BRCA1 is not essential for mammalian cell viability or homology-directed repair of double-strand DNA breaks.

Authors:  Latarsha J Reid; Reena Shakya; Ami P Modi; Maria Lokshin; Jiin-Tsuey Cheng; Maria Jasin; Richard Baer; Thomas Ludwig
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-16       Impact factor: 11.205

8.  A DNA-damage selective role for BRCA1 E3 ligase in claspin ubiquitylation, CHK1 activation, and DNA repair.

Authors:  Ko Sato; Elayanambi Sundaramoorthy; Eeson Rajendra; Hiroyoshi Hattori; Anand D Jeyasekharan; Nabieh Ayoub; Ralph Schiess; Ruedi Aebersold; Hiroyuki Nishikawa; Anna S Sedukhina; Haruka Wada; Tomohiko Ohta; Ashok R Venkitaraman
Journal:  Curr Biol       Date:  2012-08-02       Impact factor: 10.834

9.  BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.

Authors:  Rinske Drost; Peter Bouwman; Sven Rottenberg; Ute Boon; Eva Schut; Sjoerd Klarenbeek; Christiaan Klijn; Ingrid van der Heijden; Hanneke van der Gulden; Ellen Wientjens; Mark Pieterse; Aurelie Catteau; Pete Green; Ellen Solomon; Joanna R Morris; Jos Jonkers
Journal:  Cancer Cell       Date:  2011-12-13       Impact factor: 31.743

10.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Authors:  Peter C Fong; David S Boss; Timothy A Yap; Andrew Tutt; Peijun Wu; Marja Mergui-Roelvink; Peter Mortimer; Helen Swaisland; Alan Lau; Mark J O'Connor; Alan Ashworth; James Carmichael; Stan B Kaye; Jan H M Schellens; Johann S de Bono
Journal:  N Engl J Med       Date:  2009-06-24       Impact factor: 91.245
View more
  3 in total

1.  The Lys63-deubiquitylating Enzyme BRCC36 Limits DNA Break Processing and Repair.

Authors:  Hoi-Man Ng; Leizhen Wei; Li Lan; Michael S Y Huen
Journal:  J Biol Chem       Date:  2016-06-10       Impact factor: 5.157

2.  Distinct functional roles for the two SLX4 ubiquitin-binding UBZ domains mutated in Fanconi anemia.

Authors:  Christophe Lachaud; Dennis Castor; Karolina Hain; Ivan Muñoz; Jamie Wilson; Thomas J MacArtney; Detlev Schindler; John Rouse
Journal:  J Cell Sci       Date:  2014-05-02       Impact factor: 5.285

3.  The Role of Genetic Polymorphisms as Related to One-Carbon Metabolism, Vitamin B6, and Gene-Nutrient Interactions in Maintaining Genomic Stability and Cell Viability in Chinese Breast Cancer Patients.

Authors:  Xiayu Wu; Weijiang Xu; Tao Zhou; Neng Cao; Juan Ni; Tianning Zou; Ziqing Liang; Xu Wang; Michael Fenech
Journal:  Int J Mol Sci       Date:  2016-06-24       Impact factor: 5.923
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.